||Rapid Review Complete
||Tebentafusp is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tebentafusp compared with the current standard of care.